Sigma Healthcare reports 12.1% Chemist Warehouse sales growth as international stores surge 30.2%

Sigma Healthcare Limited (ASX: SIG), the Australian pharmacy distribution and retail franchising group behind Chemist Warehouse, has reported 12.1% growth in Australian Chemist Warehouse-branded store sales for the financial year to 16 October 2026. The 21 October annual general meeting trading update showed Australian like-for-like store sales increasing 9.8%, while international Chemist Warehouse-branded store sales rose 30.2% in constant currency during the three months ended 30 September. International like-for-like sales increased 15.8%, indicating that existing overseas stores contributed strongly alongside network expansion. Management expects double-digit Chemist Warehouse-branded store sales growth for the remainder of the first half, although consumer spending pressure remains evident in discretionary categories such as fragrances, vitamins and supplements.

How did Chemist Warehouse achieve 12.1% sales growth across its Australian store network?

Sigma Healthcare reported Australian Chemist Warehouse-branded store sales growth of 12.1% for the period from 1 July to 16 October 2026. Like-for-like sales increased 9.8%, demonstrating that most of the growth was not solely attributable to newly opened stores. Like-for-like performance provides a more direct indication of trading activity across comparable locations. However, sales growth does not establish an equivalent increase in operating profit because purchasing costs, promotional activity and store expenses can change.

The 2.3-percentage-point difference between total and like-for-like sales growth suggests that network changes contributed to the overall increase. That difference should not be interpreted as a precise measure of new-store revenue because the comparison bases and other adjustments may differ. Nevertheless, the data indicate that both existing stores and network expansion are supporting Australian sales. Continued growth across both channels would provide a stronger platform for revenue development.

Chemist Warehouse operates a discount-oriented pharmacy retail model with substantial exposure to prescription medicines, health products and consumer categories. The breadth of its offering can support customer visits during periods when households are more selective about spending. Management has highlighted the resilience of the business during a challenging consumer environment. However, customer activity and the margin generated from different product categories remain important to the financial outcome.

The update covers branded retail store sales rather than a complete consolidated financial statement for Sigma Healthcare. Not every dollar spent by a customer at a franchised pharmacy necessarily becomes revenue recognised by the listed company under the same accounting treatment. The economic relationship depends on distribution, franchise and ownership arrangements. Full financial results will provide a clearer measure of how retail trading converts into Sigma Healthcare’s reported earnings.

Why are international Chemist Warehouse sales growing faster than the Australian business?

International Chemist Warehouse-branded stores recorded sales growth of 30.2% in constant currency during the September quarter. Like-for-like sales increased 15.8%, indicating strong performance at existing stores as well as growth associated with changes to the network. Both measures exceeded the comparable Australian growth rates. The results highlight the potential importance of overseas markets to Chemist Warehouse’s longer-term expansion.

Constant-currency reporting removes the effect of exchange rate movements from the comparison. This helps distinguish changes in underlying store activity from movements caused by translating foreign sales into Australian dollars. However, actual consolidated earnings will still be influenced by exchange rates where overseas financial results are translated into the group’s reporting currency. The difference is relevant when assessing international performance.

Chemist Warehouse has been expanding beyond Australia into markets including New Zealand and selected Asian jurisdictions. The group is approaching a global network of 1,000 pharmacy stores across its different branded operations. Operating in additional countries can increase customer reach and purchasing scale, but it also introduces different regulatory and market conditions. Pharmacy ownership rules, medicine distribution arrangements and retail competition can vary significantly between jurisdictions.

The international like-for-like growth rate suggests that established stores are gaining sales rather than relying entirely on openings. However, a high rate of growth can also reflect the characteristics of the comparison period and the maturity of the overseas network. Sustained growth will depend on local customer adoption, store economics and the availability of suitable expansion locations. The company’s financial reporting will be important for determining the profitability of that expansion.

How are GLP-1 medicines, beauty products and healthcare demand influencing Chemist Warehouse’s sales mix?

Sigma Healthcare identified strong trading across beauty, healthcare and products associated with GLP-1 treatment. These categories helped offset weaker demand in selected discretionary areas. Management reported softness in women’s fragrances, vitamins and supplements as customers adjusted spending priorities in response to cost-of-living pressures. The contrast shows that pharmacy retail demand remains uneven even when overall branded store sales are growing.

GLP-1 medicines are used in prescribed treatment for conditions including type 2 diabetes and, for certain products and indications, weight management. The growing use of these therapies can affect pharmacy purchasing patterns and related consumer demand. Sigma Healthcare has indicated that its network continues to benefit from products associated with GLP-1 treatment. However, it has not disclosed a separate revenue or profit contribution from that category in the October update.

The company also noted that it had moved beyond the initial structural uplift associated with the introduction of GLP-1 sales. This makes the recent store performance more informative because the comparison increasingly includes sales activity from the prior period. Management expects oral GLP-1 formulations to become available during the second half of FY27 and believes they may improve treatment accessibility. Actual product availability will depend on the relevant approvals, supply arrangements and clinical indications.

The financial benefit from prescription medicines can differ from that of beauty or other consumer products. Medicine pricing, reimbursement arrangements and pharmacy distribution economics affect the amount of revenue and margin retained. Strong demand in one category does not guarantee that total gross margins improve. The product mix will therefore be important when Sigma Healthcare reports its next full financial results.

Can Sigma Healthcare continue expanding its Australian Chemist Warehouse, Amcal and Discount Drug Stores networks?

Sigma Healthcare has outlined plans to add stores across several pharmacy brands during the first half of FY27. It expects to onboard 14 Chemist Warehouse stores and 42 Amcal and Discount Drug Stores locations in Australia. A further 19 stores are expected to be added internationally. These figures represent planned network additions rather than a confirmation that every location has already commenced trading.

The growth strategy involves more than expanding Chemist Warehouse alone. Sigma Healthcare has identified opportunities to strengthen Amcal and Discount Drug Stores through brand renewal and improved commercial performance. This could broaden the group’s participation across different pharmacy customer segments. However, each brand has different competitive characteristics and operating requirements.

Management has indicated that Chemist Warehouse-branded stores represent less than 10% of Australia’s more than 5,900 community pharmacy licences. That comparison suggests room for network expansion, but it should not be interpreted as an achievable market share target. Pharmacy ownership and location arrangements operate within a regulated environment, while new stores also require commercially viable locations and suitable operators. Future expansion will depend on those constraints.

The company’s scale may provide advantages in procurement, marketing and distribution. A larger network can increase product volumes handled through the supply chain, potentially supporting operating efficiencies. However, expansion can also require additional investment in inventory, logistics and store support. The return on growth will depend on whether incremental sales produce attractive margins after those expenses.

What does the Chemist Warehouse and Sigma Healthcare combination mean for future earnings?

The combination of Sigma Healthcare and Chemist Warehouse created a large integrated pharmacy-related group with distribution, franchising and retail exposure. The enlarged business has access to an extensive pharmacy network and established supply relationships. This scale may support purchasing efficiencies and broader distribution capabilities. However, integrating operations requires ongoing attention to systems, logistics and commercial arrangements.

The latest sales figures provide evidence of strong activity within the Chemist Warehouse-branded network. They do not provide a complete assessment of group profitability, because Sigma Healthcare also operates distribution and other pharmacy-related businesses. Wholesale revenue, franchise-related income and operating costs may change differently from retail store sales. The company’s full financial statements remain necessary for evaluating margins and cash generation.

International expansion may provide additional growth opportunities while requiring investment in developing markets. Similarly, revitalising Amcal and Discount Drug Stores could improve domestic network performance if customer demand and retailer participation respond positively. The financial benefits remain dependent on execution. The company’s ability to generate sustainable earnings growth will be determined by the profitability of the combined operations rather than store sales alone.

What will determine whether Chemist Warehouse maintains double-digit growth through the Christmas trading period?

Sigma Healthcare expects Chemist Warehouse-branded stores to deliver double-digit sales growth for the remainder of the first half. The Christmas trading period is important because beauty, fragrances and other gift-related categories can experience seasonal demand. However, those are also among the categories where management has observed some consumer caution. The final trading mix will therefore influence the financial contribution from the period.

The strength of existing stores provides support for management’s confidence. Australian like-for-like growth of 9.8% and international growth of 15.8% indicate that customers are spending more across comparable locations. However, continued growth at those rates is not guaranteed. Competition, consumer budgets and product availability may affect future results.

The next important financial evidence will be Sigma Healthcare’s first-half results, including revenue, margins and cash flow across its enlarged operations. Confirmation of the planned store additions would provide another measure of network execution. Strong sales growth alongside improved earnings would support the company’s expansion strategy more convincingly than additional store numbers alone. The October update establishes positive retail momentum while leaving the precise group profit impact to be demonstrated.

Key takeaways from Sigma Healthcare’s October 2026 Chemist Warehouse trading update

• Australian Chemist Warehouse-branded store sales increased 12.1%.
• Australian like-for-like sales grew 9.8%.
• International branded store sales increased 30.2% in constant currency.
• International like-for-like sales increased 15.8%.
• Beauty, healthcare and GLP-1-related categories supported trading.
• Women’s fragrances, vitamins and supplements experienced weaker discretionary demand.
• The global pharmacy network is approaching 1,000 stores.
• First-half Australian onboarding plans include 14 Chemist Warehouse and 42 Amcal and Discount Drug Stores locations.
• Nineteen additional international stores are planned for the first half.
• Management expects double-digit Chemist Warehouse-branded store sales growth over the remainder of the period.